Literature DB >> 17000658

The epidermal growth factor receptor pathway: a model for targeted therapy.

Maurizio Scaltriti1, José Baselga.   

Abstract

The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase receptor that is frequently expressed in epithelial tumors. The EGFR was the first receptor to be proposed as a target for cancer therapy, and after 2 decades of intensive research, there are several anti-EGFR agents available in the clinic. Recent advances in our understanding in the mechanisms of receptor activation and function, discovery of primary and secondary EGFR somatic mutations, as well as a new generation of anti-EGFR agents provide new leads on the clinical targeting of this receptor and may serve as a model for strategies aimed at targeting other receptors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17000658     DOI: 10.1158/1078-0432.CCR-05-1554

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  273 in total

Review 1.  Pharmacokinetic and pharmacodynamic perspectives on the clinical drug development of panitumumab.

Authors:  Bing-Bing Yang; Peggy Lum; Alin Chen; Rosalin Arends; Lorin Roskos; Brian Smith; Juan José Pérez Ruixo
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

2.  HGF rescues colorectal cancer cells from EGFR inhibition via MET activation.

Authors:  David Liska; Chin-Tung Chen; Thomas Bachleitner-Hofmann; James G Christensen; Martin R Weiser
Journal:  Clin Cancer Res       Date:  2010-11-22       Impact factor: 12.531

Review 3.  Molecular parameters of head and neck cancer metastasis.

Authors:  Sanjay L Bhave; Theodoras N Teknos; Quintin Pan
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2011       Impact factor: 1.807

Review 4.  Growth factor signaling pathways as targets for prevention of epithelial carcinogenesis.

Authors:  Okkyung Rho; Dae Joon Kim; Karou Kiguchi; John Digiovanni
Journal:  Mol Carcinog       Date:  2010-07-20       Impact factor: 4.784

Review 5.  Defining the cancer master switch.

Authors:  Courtney J Balentine; David H Berger; Shi-He Liu; Changyi Chen; John Nemunaitis; F Charles Brunicardi
Journal:  World J Surg       Date:  2011-08       Impact factor: 3.352

Review 6.  Exploiting novel molecular targets in gastrointestinal cancers.

Authors:  Wen W Ma; Manuel Hidalgo
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

7.  Heparanase augments epidermal growth factor receptor phosphorylation: correlation with head and neck tumor progression.

Authors:  Victoria Cohen-Kaplan; Ilana Doweck; Inna Naroditsky; Israel Vlodavsky; Neta Ilan
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

8.  Transducer of erbB2.1 is a potential cellular target of gefitinib in lung cancer therapy.

Authors:  Ke-Kang Sun; Yang Yang; Lin Zhao; Li-Li Wang; Yang Jiao
Journal:  Oncol Lett       Date:  2012-10-15       Impact factor: 2.967

9.  Biphasic regulation of ENaC by TGF-{alpha} and EGF in renal epithelial cells.

Authors:  Lian Liu; Billie Jeanne Duke; Bela Malik; Qiang Yue; Douglas C Eaton
Journal:  Am J Physiol Renal Physiol       Date:  2009-03-18

10.  Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis.

Authors:  Ondrej Fiala; Veronika Veskrnova; Renata Chloupkova; Alexandr Poprach; Igor Kiss; Katerina Kopeckova; Ladislav Dusek; Lubomir Slavicek; Milan Kohoutek; Jindrich Finek; Marek Svoboda; Lubos Petruzelka; Ludmila Boubliková; Josef Dvorak; Bohuslav Melichar; Tomas Buchler
Journal:  Target Oncol       Date:  2018-12       Impact factor: 4.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.